Tofogliflozin: First Global Approval.

Link to article at PubMed

Related Articles

Tofogliflozin: First Global Approval.

Drugs. 2014 May 22;

Authors: Poole RM, Prossler JE

Tofogliflozin (Apleway(®), Deberza(®) [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.K. and Kowa. Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglcaemic agents. This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.

PMID: 24848755 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.